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Abstract
Toll-Like Receptor (TLR) -2 and -4 expression and TLR-induced cytokine response of inflammatory cells are related to
atherogenesis and atherosclerotic plaque progression. We examined whether immediate TLR induced changes in CD11b
and L-selectin (CD62L) expression are able to discriminate the presence and severity of atherosclerotic disease by exploring
single dose whole blood TLR stimulation and detailed dose-response curves. Blood samples were obtained from 125
coronary artery disease (CAD) patients and 28 controls. CD11b and L-selectin expression on CD14+ monocytes was
measured after whole blood stimulation with multiple concentrations of the TLR4 ligand LPS (0.01–10 ng/ml) and the TLR2
ligand P3C (0.5–500 ng/ml). Subsequently, dose-response curves were created and the following parameters were
calculated: hillslope, EC50, area under the curve (AUC) and delta. These parameters provide information about the
maximum response following activation, as well as the minimum trigger required to induce activation and the intensity of
the response. CAD patients showed a significantly higher L-selectin, but not CD11b response to TLR ligation than controls
after single dose stimulations as well as significant differences in the hillslope and EC50 of the dose-response curves. Within
the CAD patient group, dose-response curves of L-selectin showed significant differences in the presence of hypertension,
dyslipidemia, coronary occlusion and degree of stenosis, whereas CD11b expression had the strongest discriminating power
after single dose stimulation. In conclusion, single dose stimulations and dose-response curves of CD11b and L-selectin
expression after TLR stimulation provide diverse but limited information about atherosclerotic disease severity in stable
angina patients. However, both single dose stimulation and dose-response curves of LPS-induced L-selectin expression can
discriminate between controls and CAD patients.
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Introduction
Atherosclerosis is an inflammatory disease in which monocytes
and macrophages play an essential role [1]. Toll-like receptors
(TLRs), abundantly expressed by most inflammatory cells, are
important for the induction of innate immune responses and can
be activated by both pathogens and endogenous ligands. TLRs,
and especially TLR2 and TLR4, are involved in the initiation and
progression of atherosclerotic disease. Multiple studies have shown
that TLR2 and TLR4 are up-regulated in atherosclerotic plaques
and circulating monocytes and that this enhanced expression is
associated with more severe atherosclerotic disease [2–5]. Both
TLR2 and TLR4 expression as well as the inflammatory response
following TLR ligation, differ among individuals and may
correlate with clinical presentation. Previous studies demonstrated
that isolated monocytes from patients with unstable angina (UA)
and acute myocardial infarction (AMI) produce higher levels of
B7-1 and Interleukin-12 (IL-12) following LPS stimulation [6] and
patients with UA showed an enhanced TLR response of
circulating monocytes after whole-blood LPS stimulation, as
assessed by IL-6 secretion [7]. Moreover, an increased response
to TLR activation seems to be associated with atherosclerotic
disease severity which was shown in a cohort of patients with stable
angina (SA) [8].
However, comparisons of reported results are cumbersome due
to the use of non-standardized protocols with different incubation
times and readouts to assess TLR responsiveness. For potential
clinical application of TLR responsiveness as a measure of disease
severity, standardization is therefore mandatory. In most previous
studies the activation status of inflammatory cells following TLR
ligation was assessed after stimulation with a single, high
concentration of a TLR ligand. However, dose-response curves
might differ among individuals not only in terms of maximum
activation, but also in the steepness of the response with increasing
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dosage and in the minimum ligand concentration needed to
induce an inflammatory response.
Furthermore, the majority of studies in coronary artery disease
(CAD) patients used cytokine release as read-out for TLR
response. This usually requires incubations of several hours,
which is less favorable for diagnostic testing. Hence, activation
markers that respond quickly after TLR activation and for which
no de novo protein synthesis is needed seem more appropriate for
successful future applications.
CD11b and L-selectin (CD62L) are surface activation markers
and play a role in the adhesion of inflammatory circulating
monocytes and neutrophils, which is an important step in the
initiation of atherosclerosis. L-selectin is mainly involved in
leukocyte rolling over endothelium while CD11b is responsible
for subsequent firm adhesion [9–12]. Circulating leukocytes
express both markers also under normal circumstances, but
expression is quickly changed by inflammatory stimuli. Upon
activation, CD11b levels are usually up-regulated while L-selectin
is shed from the cell surface releasing an active soluble form in the
circulation [13,14]. Both markers have been associated with
atherosclerotic disease in several reports [15–17].
In this exploratory study, we assessed whether single dose
response and detailed dose-response curves of TLR2 and -4
induced CD11b and L-selectin expression differs between patients
and controls. Furthermore, we explored the potential diagnostic
and prognostic value of TLR response by studying the associations
between TLR responsiveness patterns and clinical characteristics.
Methods
Study Population
For this study, 125 consecutive patients were enrolled who were
scheduled for coronary angiography in the University Medical
Hospital Utrecht between July 2009 and May 2011. As a control
group, male individuals above 50 years without manifest coronary
artery disease were included from the Military Hospital of the
University Medical Hospital Utrecht. Exclusion criteria were
currently present active inflammatory conditions, autoimmune
disease, malignancies, use of immunosuppressive drugs and known
hematological disorders. Clinical parameters were collected from
case record forms including coronary angiograms. The ethics
committee of the University Medical Centre Utrecht approved the
protocol and all participants provided written informed consent
prior to participation.
After 9 months, patients were approached to evaluate the
occurrence of secondary events, after which endpoints were
further verified. Primary endpoints were defined as the occurrence
of cardiovascular death, myocardial infarction (MI), percutaneous
coronary intervention (PCI), coronary artery bypass grafting
(CABG) or cerebrovascular accident (CVA).
Blood Sampling
Whole blood samples were collected in lithium-heparinized
(LH) anti-coagulated tubes. To minimize the effects of the
procedure on sample activation, patient samples were obtained
prior to catheterization and administration of heparin therapy.
Expression of Activation Markers CD11b and L-selectin
after TLR Stimulation Measured by Flow Cytometry
Whole blood samples were stimulated directly after collection
with increasing concentrations of either lipopolysaccharide (LPS;
TLR4) (0.01, 0.1, 1, 10 ng/ml) or P3C (TLR2) (0.5, 5, 50,
500 ng/ml) for 15 min at 37uC and 5% CO2. PBS incubation
served as a control to determine baseline expression. Stimulated
samples were stained for CD14 (PE-Cy5, Beckman Coulter),
CD11b (PE-Cy7, eBioscience) and L-selectin (ECD, Beckman
Coulter) for 20 min. Expression levels of CD11b and L-selectin
were determined within the CD14+ population by flow cytometry
(FC500, Beckman Coulter). Average fluorescent intensity per cell
is expressed as mean fluorescence intensity (MFI). A cut-off of at
least 300 CD14+ monocytes was chosen to be included in the
analysis.
Dose-response Curves
Combined dose-response curves of patients and controls were
created based on the mean CD11b and L-selectin expression per
concentration to assess the effect of the presence of cardiovascular
disease on TLR responsiveness (sigmoidal dose response curves
with variable slope, Graphpad prism 5).
Baseline expression (after PBS stimulation) of CD11b and L-
selectin varied significantly among individuals. To enable
discrimination of response types (i.e. hypo2/hyperresponse) in
relation to clinical characteristics, irrespective of baseline marker
expression, delta values (difference in expression levels between
baseline and after stimulation with each concentration of the
ligand) were calculated to determine the actual TLR response.
Subsequently, dose-response curves were created for each in-
dividual (sigmoidal dose response curves with variable slope,
Graphpad prism 5). Dose response curves created from these
values will be referred to as delta CD11b or delta L-selectin.
The following derivatives were calculated for each curve
(Figure 1A):
N Hillslope =maximum steepness of the dose-response curve
N EC50 = concentration of the ligand resulting in half-
maximum activation
N Area Under the Curve (AUC) = area under the dose-
response curves
N Delta = difference between baseline and maximum expres-
sion levels
Dose-response curves that were ambiguous or did not reach
a plateau at high LPS concentrations resulting in an unreliable
delta, AUC and EC50 were excluded (n = 18 for CD11b; n= 6 for
L-selectin, all CAD patients). For the P3C stimulations we did not
assess the different patterns in the dose response curves.
Statistics
SPSS version 20.0 (Chicago, IL, USA) was used for all statistical
analyses. Baseline characteristics of CAD patients and controls
were compared with Chi-square, Fisher exact or Mann Whitney U
test where appropriate. As responsiveness data were not normally
distributed, non-parametric testing was performed. Dichotomous
clinical variables were categorized in two groups and Mann-
Whitney U test performed. For continuous clinical variables
Spearman correlation was used. To determine the effect of risk
factors and medication use on the measures of responsiveness, we
executed a linear regression (enter model) comparing controls and
CAD patients. In addition, a backward linear regression was
performed to assess which key patient phenotypes (risk factors and
clinical determinants) drive the differences in TLR responsiveness
in CAD patients. A two-sided p-value ,0.05 was considered
statistically significant.
Results
Baseline clinical characteristics of the 125 coronary artery
disease (CAD) patients and 28 controls are reported in Table 1.
Toll-Like Receptor Response in Coronary Disease
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Despite all attempts to include age-matched subjects, controls were
significantly younger (average age: 53.3 vs. 61.3 years). Further-
more, controls presented with significantly less risk factors and less
medication use was reported.
Dose-response curves of the activation markers CD11b and L-
selectin were constructed for each individual after stimulation with
increasing concentrations of LPS and P3C. As demonstrated in
Figure 1B, dose-response curves markedly varied among individ-
uals.
TLR Response CAD Patients vs. Controls
In all subjects, CD11b expression increased and L-selectin
expression decreased after TLR stimulation. Combined dose-
response curves of controls and CAD patients are illustrated in
Figure 2. CAD patients showed to be more responsive to TLR
ligands, indicated by a higher CD11b expression particularly at
intermediate concentrations and a faster and more extensive L-
selectin shedding.
Single dose stimulation only significantly differed between
controls and CAD patients for L-selectin after LPS 0.1 ng/ml
stimulation (Table 2). Dose-response curves showed that CAD
patients have a significantly lower hillslope for L-selectin and
a lower EC50 for both markers compared to controls. This
indicates that circulating monocytes of patients need a lower
trigger to become activated, but once activated, the response of
controls is more extensive (Table 2). The differences in LPS-
induced L-selectin response between controls and CAD patients
(both after single dose stimulation and derivatives of dose-response
curves) become even more evident after correction for risk factors
and medication use (Table 3). Next to the differences between
CAD patients and controls, we also investigated whether the
observed variation in TLR-responsiveness among patients could
be explained by clinical characteristics, such as cardiovascular risk
factors, atherosclerotic disease severity and secondary cardiovas-
cular events, by analyzing single dose stimulations and dose
response curves.
Figure 1. Derivatives of dose-response curves. A. From each dose-response curve, four different derivatives can be calculated to assess TLR-
responsiveness: hillslope (maximum steepness of the curve), EC50 (ligand concentration resulting in half-maximum activation), area under the curve
(AUC) and the delta (difference between minimum and maximum expression levels). B. Representative selection of CD11b and L-selectin response
curves from individual patients showing high inter-individual variability after LPS stimulation.
doi:10.1371/journal.pone.0060467.g001
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Single dose TLR Stimulation in CAD Patients
Two fixed concentrations of LPS (0.01 and 10 ng/ml), P3C (5
and 500 ng/ml) and PBS control were selected to study differences
between patients in TLR-induced CD11b (Table S1A) and L-
selectin (Table S1B) expression. Patients with a Body Mass Index
(BMI) above 25 showed a significantly higher CD11b expression
after TLR2 stimulation than normal-weight subjects (P3C 5: MFI
9.0 vs. MFI 7.2, p = 0.020; P3C 500: MFI 15.9 vs. MFI 13.5,
p = 0.046) (Figure 3). Also when BMI was tested as a continuous
variable, a strong correlation could be observed with TLR2-
induced CD11b expression (data not shown). Other continuous
parameters, such as age, CRP, and lipids, did not show relevant
correlations with TLR-induced CD11b and L-selectin expression
(data not shown).
To determine which clinical characteristics and risk factors act
as key factors in the TLR response we performed a backward
regression model. The higher CD11b expression after TLR2
stimulation in patients with a BMI.25 remained significant after
correction for other factors. Additionally, we observed higher
CD11b expression levels in unstable CAD patients as compared to
patients with stable angina after correction for risk factors and
angiographic parameters. These differences reached significance
for TLR2 stimulations.
Dose-response Curves in CAD Patients
Within the CAD patient cohort, CD11b response after LPS
stimulation showed a significantly higher hillslope in females (Table
S2A).ForL-selectin, significantdifferenceswereobservedforpatients
with hypertension, dyslipidemia, occlusion and degree of stenosis
(Table S2B). Patients with a stenosis .90% had a lower median
hillslope (1.34 vs. 1.67, p = 0.007) andahighermedianAUC (12.4 vs.
10.5, p = 0.018) and delta (6.6 vs. 5.6, p = 0.016) (Figure 4A).
Furthermore, patients with hypertension showed a lower respon-
siveness as indicated by a higher EC50 (0.09 vs. 0.14, p= 0.037) and
lowerAUC (12.3 vs. 10.9, p = 0.042) (Figure 4B).Continuous clinical
parameters did not show any significant correlations with dose-
responsiveness (data not shown). After correction for risk factors and
angiographic parameters, we could no longer detect consistent
associations between specific clinical characteristics and the different
readouts for TLR response.
Table 1. Baseline characteristics of CAD patients and controls.
Patient cohort Controls p-value
(n =125) (n=28)
Risk factors
Age, mean 6 SD, y 61.369.3 53.362.8 ,0.001
Male gender 98 (78.4%) 28 (100%) 0.008
Current smoker 16 (12.8%) 6 (21.4%) 0.241
Diabetes 16 (12.8%) 0 (0%) 0.077
Hypertension 83 (66.4%) 9 (32.1%) 0.013
Dyslipidemia 78 (62.4%) 5 (17.9%) ,0.001
BMI, mean 6 SD, kg/m2 27.965.2 27.263.1 0.733
eGFR (MDRD), mean 6 SD, ml/min/1.73 m2 81.5632.7 119.3623.1 0.016
Previous PCI/MI 60 (48.0%) 2 2
Clinical presentation
Confirmed diagnosis
SA 113 (90.4%) 2 2
UA/NSTEMI 12 (9.6%) 2 2
Angiographic parameters
Multi vessel disease (stenosis .50%) 70 (56.0%) 2 2
Highest degree of stenosis .90% 49 (39.2%) 2 2
Occlusion 33 (26.4%) 2 2
Follow-up
Primary endpoint 17 (13.6%) 2 2
Medication use
Beta-blocker 103 (82.4%) 4 (14.3%) ,0.001
ACE inhibitor 55 (44.0%) 3 (10.7%) 0.005
Ca-antagonist 34 (27.2%) 0 (0%) 0.004
ATII antagonist 21 (16.8%) 2 (7.1%) 0.531
Statin 97 (77.6%) 1 (3.6%) ,0.001
ASA 113 (90.4%) 1 (3.6%) ,0.001
Clopidogrel 106 (84.8%) 0 (0%) ,0.001
BMI, body mass index; eGFR, estimated glomerular filtration rate; PCI, percutaneous coronary intervention; MI, myocardial infarction; SA, stable angina pectoris; UA,
unstable angina pectoris; NSTEMI, non-ST-elevated myocardial infarction; ASA, acetylsalicylic acid.
doi:10.1371/journal.pone.0060467.t001
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Figure 2. Dose-response curves of CAD patients and controls. Mean dose-response curves of CAD patients (dashed line) vs. controls
(continuous line) for CD11b (upper panel) and L-selectin (lower panel). Samples were either stimulated with increasing concentrations of LPS (left
hand panel) or P3C (right hand panel). PBS stimulation served as a control (LPS concentration= 0). Concentrations are log-transformed. Data are
presented as mean 6 S.E.M.
doi:10.1371/journal.pone.0060467.g002
Table 2. CD11b and L-selectin expression of CAD patients and controls.
CD11b Controls CAD patients p-value L-selectin Controls CAD patients p-value
PBS 3.4 [2.0] 3.0 [1.8] 0.126 PBS 6.3 [2.0] 5.8 [2.9] 0.095
LPS 0.01 6.1 [7.2] 9.3 [7.1] 0.118 LPS 0.01 6.6 [1.9] 6.1 [2.9] 0.148
LPS 0.1 14.3 [5.2] 15.4 [7.8] 0.178 LPS 0.1 5.1 [2.8] 3.7 [2.9] 0.003*
LPS 1 17.6 [5.1] 17.9 [6.9] 0.592 LPS 1 0.82 [1.1] 0.66 [0.5] 0.153
LPS 10 19.0 [5.6] 19.1 [8.1] 0.694 LPS 10 0.45 [0.3] 0.47 [0.2] 0.438
P3C 0.5 5.4 [3.1] 6.0 [4.2] 0.688 P3C 0.5 6.2 [1.9] 5.6 [2.4] 0.161
P3C 5 7.5 [4.8] 8.4 [8.3] 0.434 P3C 5 6.2 [1.9] 5.7 [2.7] 0.177
P3C 50 11.7 [5.9] 12.3 [9.0] 0.540 P3C 50 5.0 [4.3] 3.7 [5.5] 0.092
P3C 500 16.6 [4.1] 15.2 [5.9] 0.243 P3C 500 0.96 [1.9] 0.64 [1.2] 0.120
LPS Hillslope 1.01 [0.67] 0.78 [0.46] 0.162 LPS Hillslope 1.86 [9.3] 1.39 [1.01] 0.037*
LPS EC50 0.06 [0.07] 0.03 [0.05] 0.003** LPS EC50 0.21 [0.73] 0.11 [0.14] 0.004**
LPS AUC 34.4 [13.6] 36.9 [15.8] 0.469 LPS AUC 10.2 [7.4] 11.4 [5.3] 0.424
LPS Delta 15.6 [5.0] 16.0 [7.0] 0.689 LPS Delta 6.1 [2.5] 5.9 [2.6] 0.416
Expression levels of CD11b and L-selectin of CAD patients vs. controls at baseline and after TLR stimulation. Data are presented as median [IQR].
*p,0.05.
**p,0.01.
doi:10.1371/journal.pone.0060467.t002
Toll-Like Receptor Response in Coronary Disease
PLOS ONE | www.plosone.org 5 April 2013 | Volume 8 | Issue 4 | e60467
Discussion
Stimulation of TLRs results in the production and release of
pro-inflammatory cytokines and promotes adhesion of circulating
leukocytes, which are essential in the development and progression
of atherosclerotic plaques. In the present study, we measured
TLR-induced CD11b and L-selectin expression on circulating
monocytes to assess whether changes of these fast responding
markers are able to distinguish between CAD patients and controls
or among patients. Furthermore, we hypothesized that detailed
TLR-induced dose-responsiveness patterns could be a better
measure of activation response than single dose TLR stimulation.
We show that the up-regulation of CD11b expression and
shedding process of L-selectin already occurs within 15 minutes
after both TLR2 and TLR4 stimulation in all individuals. In
addition, our data show that dose-response curves, but not single
dose TLR stimulation, reveal significant differences between
controls and CAD patients after univariate testing. Circulating
monocytes of CAD patients seemed to be more easily activated as
reflected by the significantly lower EC50 for both CD11b and L-
selectin. In contrast, baseline and maximum expression levels did
not differ between both groups, supporting an added value of dose
response curves rather than single dose stimulation for discrim-
ination of CAD patients and controls. However, multivariate
regression analysis showed that also single dose LPS stimulations
as measured by L-selectin expression, as well as the hillslope and
EC50 calculated from the dose-response curves significantly differ
between CAD patients and controls. This suggests that the
differences in L-selectin response after LPS stimulation were
masked by risk profiles and medication use. Thus, LPS induced L-
selectin shedding is capable of distinguishing between controls and
CAD patients, either after single dose response or dose response
curve derivatives.
CD11b and L-selectin response after TLR stimulation varied
widely among patients. Hence, we speculated that this wide
variation might provide information about the individual disease-
state or the likelihood of future events. One low and one high
concentration of LPS (0.1 and 10 ng/ml) and P3C (5 and 500 ng/
ml) were selected to explore single dose CD11b and L-selectin
responsiveness among CAD patients. Median TLR2-induced
CD11b expression was higher in patients with a BMI above 25
compared to normal-weight subjects for single dose TLR
stimulation for both concentrations of P3C. This concurs with
our previous study showing an increased TLR-induced TNFa
response in obese patients undergoing PCI or carotid endarter-
ectomy (CEA) and an increased CD11b response after TLR
stimulation in patients undergoing CEA [18]. Other clinical and
angiographic parameters did not show any significant differences
after univariate testing, which is in line with Servi et al., who also
found no association of baseline monocyte CD11b expression with
clinical factors. However, in their study, CD11b expression tended
to be higher in patients with angiographic complex lesion
morphology [19]. Multivariate testing showed that unstable
angina or NSTEMI patients had significantly higher CD11b
Table 3. CD11b and L-selectin expression of CAD patients
and controls adjusted for risk factors and medication use.
CD11b B b p-valueL-selectinB b p-value
PBS 20.653 20.112 0.467 PBS 21.709 20.344 0.030*
LPS 0.01 3,267 0.260 0.089 LPS 0.01 21.696 20.338 0.033*
LPS 0.1 2.077 0.152 0.307 LPS 0.1 22.756 20.520 0.001**
LPS 1 1.994 0.143 0.344 LPS 1 21.350 20.765 ,0.001**
LPS 10 2.650 0.184 0.220 LPS 10 20.648 20.971 ,0.001**
P3C 0.5 20.024 20.002 0.987 P3C 0.5 21.338 20.295 0.064
P3C 5 20.448 20.036 0.814 P3C 5 21.928 20.372 0.014*
P3C 50 0.095 0.007 0.966 P3C 50 21.386 20.194 0.218
P3C 500 1.566 0.118 0.441 P3C 500 20.815 0.196 0.228
LPS
Hillslope
21.735 20.279 0.101 LPS
Hillslope
23.452 20.445 0.005**
LPS EC50 0.291 0.167 0.324 LPS EC50 20.421 20.624 ,0.001**
LPS AUC 8.798 0.293 0.080 LPS AUC 0.753 20.063 0.702
LPS Delta 2.803 0.229 0.169 LPS Delta 20.902 20.182 0.271
Differences in CD11b and L2selectin expression levels between CAD patients
and controls after correction for risk factors and medication use further defined
as age, gender, smoking, diabetes, hypertension, dyslipidemia, BMI, eGFR,
betablocker, ACE inhibitors, Ca-antagonist, ATII antagonist, statin, ASA,
clopidogrel. Data are presented as median [IQR].
*p,0.05.
**p,0.01.
doi:10.1371/journal.pone.0060467.t003
Figure 3. Single dose TLR response in relation to BMI. CD11b expression after stimulation with P3C 5 ng/ml (left) and P3C 500 ng/ml (right)
was significantly higher in patients with a BMI.25 as compared to normal weight patients (BMI,25). Whiskers are presented as 5–95 percentile. Data
were statistically tested with a Mann Whitney U test.
doi:10.1371/journal.pone.0060467.g003
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levels than stable angina patients. This suggests that CD11b may
not be a good marker to discriminate subgroups of stable angina
patients, but might reflect more advanced atherosclerosis.
Data about the role of membrane bound L-selectin in
cardiovascular patients is scarce. Several studies suggest an
important role of L-selectin in atherogenesis, but data from
clinical studies are limited [1,20,21]. In patients with ischemic
stroke, soluble L-selectin levels were significantly increased
suggesting a higher circulating cell response accompanied by L-
selectin shedding [20].
Derivatives of L-selectin dose-response curves show significant
differences for hypertension, dyslipidemia, occlusion and degree of
stenosis, the association with the latter being the strongest. Patients
with a coronary stenosis above 90% had a significantly lower
hillslope and a higher AUC and delta, suggesting a higher
responsiveness in these patients. This observation is in line with
our previous study where we describe a higher TLR-induced
TNFa response in patients with a stenosis above 90% [8].
Surprisingly, patients with hypertension displayed a lower TLR
response. However, antihypertensive drugs used by the majority of
these patients could explain this effect. Furthermore, our data
show that more severely diseased patients based on coronary
angiograms and clinical presentation, have a lower hillslope for
both activation markers and a higher AUC and delta for L-
selectin. After multivariate testing, none of the univariate
associations remained valid except for the lower AUC of
hypertensive patients.
The significant but subtle differences in TLR-induced CD11b
and L-selectin responsiveness will likely not suffice to discriminate
between individual patients at low or high risk to suffer from CAD
in a clinical setting. The majority of patients in our cohort
presented with stable angina, and therefore the differences
between these individuals might be too small for these markers
to clearly discriminate between individual patients in both groups.
This is supported by previous studies in which baseline CD11b
expression was up-regulated in patients with UA and ACS but no
significant differences were found between SA and controls
[16,22].
In previous studies, others and our group have demonstrated
that processes occurring in the vascular wall can affect the TLR-
responsiveness of circulating cells as measured by cytokine release.
In these studies, a reduction in TLR-induced cytokine release
shortly after PCI, vascular surgery and myocardial ischemia was
observed [8,23,24], suggesting that vascular injury and ischemia
influences the TLR-response of circulating cells. Furthermore, it
has been reported that TLR-response alters with progression of
atherosclerotic disease [8] and in patients with unstable angina as
compared to stable angina [6,7]. We show that CD11b and L-
selectin expression levels after TLR stimulation are also capable of
discriminating between patients, even though they are potentially
less sensitive than TLR-induced cytokine levels.
In conclusion, dose-response curves and single dose stimulations
of LPS-induced L-selectin expression can discriminate between
controls and CAD patients. Furthermore, single dose stimulations
and dose-response curves of CD11b and L-selectin expression
provide diverse information. Where more associations with clinical
characteristics were found for CD11b after single dose stimulation,
differences in L-selectin expression were more evident for dose-
response curves. Based on this study we cannot conclude yet which
one would be the most informative.
Limitations
For this study, multiple concentrations of TLR ligands were
used to sort out dose dependent effects of TLR ligands in
association with clinical characteristics. Our study showed positive
associations for BMI and TLR2-induced CD11b expression,
clinical presentation and CD11b expression and stenosis degree
and L-selectin dose response derivatives, but correction for
multiple testing probably would have limited the effect size. This
study should therefore be considered as an exploratory exercise to
examine clinical determinants that associate with TLR respon-
siveness. Our inferences are weakened by the large number of
comparisons and lack of significance when corrected for multiple
testing and therefore require validation in a study with a more
targeted approach.
To improve precision and accuracy of the outcome, this study
needs to be validated preferably with additional dosages in the
intermediate range. This would result in more reliable dose-
response curves and derivatives calculated from this. Dose-
response curves after TLR2 stimulation were excluded because
of too many unreliable curves. In future studies, higher concen-
trations of P3C, next to additional dosages in the intermediate
range, will be needed to investigate TLR2 induced dose-response
curves of CD11b and L-selectin in atherosclerotic patients.
Figure 4. Dose-response curves of CAD patients in relation to clinical characteristics. A. L-selectin dose-response curves of patients with
severe (.90%) coronary stenosis showed a significantly reduced hillslope and an increased AUC and delta as compared to patients with ,90%
stenosis. B. Responsiveness of L-selectin in patients with arterial hypertension was significantly less compared to normotensive patients indicated by
a reduced AUC and a higher EC50.
doi:10.1371/journal.pone.0060467.g004
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acteristics. CD11b (A) and L-selectin (B) expression after single
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istics. For the multivariate analyses a backward linear regression
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occlusion was used. Data are presented as median [IQR].
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diseased vessels, degree of stenosis, occlusion was used. Data are
presented as median [IQR]. ˆp,0.05 in univariate analysis,
*p,0.05 in multivariate analysis.
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